Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: Rationale for their use in clinical cardiology

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.

Original languageEnglish
Pages (from-to)703-709
Number of pages7
JournalMini-Reviews in Medicinal Chemistry
Volume4
Issue number7
Publication statusPublished - Sep 2004

Fingerprint

Platelet Membrane Glycoprotein IIb
Integrin beta3
Platelet Membrane Glycoproteins
Cardiology
Platelet Glycoprotein GPIIb-IIIa Complex
Platelets
tirofiban
Pharmacodynamics
Pharmacokinetics
Platelet Activation
Platelet Aggregation
Thrombosis
Blood Platelets
Agglomeration
Chemical activation

Keywords

  • Acute coronary syndromes
  • Atherosclerotic plaque
  • Glycoprotein IIb/IIIa receptor
  • Percutaneous coronary intervention
  • Platelet aggregation inhibitors

ASJC Scopus subject areas

  • Chemistry(all)
  • Medicine (miscellaneous)
  • Pharmacology

Cite this

@article{6b9e24cd01a34c56925ef5a401bf5d1f,
title = "Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: Rationale for their use in clinical cardiology",
abstract = "The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.",
keywords = "Acute coronary syndromes, Atherosclerotic plaque, Glycoprotein IIb/IIIa receptor, Percutaneous coronary intervention, Platelet aggregation inhibitors",
author = "Rossi, {Marco L.} and D. Zavalloni",
year = "2004",
month = "9",
language = "English",
volume = "4",
pages = "703--709",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor

T2 - Rationale for their use in clinical cardiology

AU - Rossi, Marco L.

AU - Zavalloni, D.

PY - 2004/9

Y1 - 2004/9

N2 - The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.

AB - The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.

KW - Acute coronary syndromes

KW - Atherosclerotic plaque

KW - Glycoprotein IIb/IIIa receptor

KW - Percutaneous coronary intervention

KW - Platelet aggregation inhibitors

UR - http://www.scopus.com/inward/record.url?scp=4344629332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344629332&partnerID=8YFLogxK

M3 - Article

C2 - 15379638

AN - SCOPUS:4344629332

VL - 4

SP - 703

EP - 709

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 7

ER -